NCT02307812Approved For Marketing不适用
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant has histologically or cytologically confirmed gastric adenocarcinoma, including gastroesophageal junction (GEJ) adenocarcinoma (Participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ.) after prior chemotherapy.
- •Acceptable prior chemotherapy regimens for this protocol are combination chemotherapy regimens that include platinum or fluoropyrimidine components (acceptable prior platinum agents are cisplatin, carboplatin, or oxaliplatin; acceptable prior fluoropyrimidine agents are 5-fluorouracil (5-FU) and capecitabine). Prior trastuzumab use in human epidermal growth factor receptor 2 positive (HER2+) participants is accepted too.
- •The participant is eligible for treatment by chemotherapy and has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
排除标准
- •Participant has a known allergy to any of the treatment components.
研究者
相似试验
已完成
1 期
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric AdenocarcinomasAdenocarcinomaNCT01253525Eli Lilly and Company6
进行中（未招募）
1 期
Avelumab + Paclitaxel/ Ramucirumab als Zweitlinientherapie beim gastro-ösophagealen Adenokarzinom: eine Phase-II-Studie der AIO - RAP-Studiemetastatic gastro-oesophageal cancerMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864EUCTR2018-002938-20-DECharite - Universitätsmedizin Berlin59
已完成
不适用
Predicting the Efficacy in Advanced Gastric Cancer.Chemotherapy EffectPaclitaxelRamucirumabGastric CancerNCT06490055City of Hope Medical Center162
进行中（未招募）
不适用
Phase II ramucirumab/paclitaxel as second-line treatment in metastatic gastric or Gastroesophageal junction adenocarcinoma with integrative genomic analysisNeoplasmsKCT0003440Samsung Medical Center61
Unknown
3 期
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction CancersStomach NeoplasmsNCT02934464Fondazione IRCCS Istituto Nazionale dei Tumori, Milano280